Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN.LN)

Astrazeneca Plc (AZN.LN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 167,125,900
  • Shares Outstanding, K 1,549,471
  • Annual Sales, $ 37,417 M
  • Annual Income, $ 112,000 K
  • 60-Month Beta N/A
  • Price/Sales 4.83
  • Price/Cash Flow 27.60
  • Price/Book 5.74
Trade AZN.LN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings 0.25 on 04/29/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 2.91 (1.90%)
  • Most Recent Dividend 1.453 on 02/24/22
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9,399.000 +13.88%
on 06/14/22
11,054.002 -3.17%
on 06/29/22
+262.000 (+2.51%)
since 06/01/22
3-Month
9,399.000 +13.88%
on 06/14/22
11,054.002 -3.17%
on 06/29/22
+628.000 (+6.23%)
since 04/01/22
52-Week
8,029.000 +33.32%
on 09/17/21
11,054.002 -3.17%
on 06/29/22
+1,962.000 (+22.44%)
since 07/01/21

Most Recent Stories

More News
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis...

AZN : 66.07 (-1.42%)
AZN.LN : 10,680.000 (-1.11%)
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...

IPHA : 2.70 (-4.26%)
AZN.LN : 10,680.000 (-1.11%)
AZN : 66.07 (-1.42%)
Angeles Equity Partners Appoints Debbie White to Xanitos Board of Directors

Angeles Equity Partners, LLC (“Angeles”), a private investment firm focused on value creation through operational transformation, today announced the appointment of Debbie White to the Board of Directors...

IRV.LN : 6.048 (-36.97%)
HWDN.LN : 605.200 (+0.43%)
AZN.LN : 10,680.000 (-1.11%)
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in...

HCM : 12.64 (+0.24%)
HCM.LN : 210.976 (+5.49%)
AZN.LN : 10,680.000 (-1.11%)
AZN : 66.07 (-1.42%)
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and...

HCM : 12.64 (+0.24%)
HCM.LN : 210.976 (+5.49%)
AZN : 66.07 (-1.42%)
AZN.LN : 10,680.000 (-1.11%)
Global Industry Executive Debbie White Joins PAVmed Board of Directors

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company,...

PAVM : 0.9347 (-2.62%)
PAVMZ : 0.5000 (+0.02%)
HWDN.LN : 605.200 (+0.43%)
IRV.LN : 6.048 (-36.97%)
AZN.LN : 10,680.000 (-1.11%)
FibroGen Provides Regulatory Update on Roxadustat

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee...

AZN : 66.07 (-1.42%)
AZN.LN : 10,680.000 (-1.11%)
FGEN : 10.56 (-3.39%)
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology

AZN.LN : 10,680.000 (-1.11%)
AZN : 66.07 (-1.42%)
ADPT : 8.09 (-1.58%)
AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development

AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.

ALXN : 182.50 (+1.70%)
AZN : 66.07 (-1.42%)
AZN.LN : 10,680.000 (-1.11%)
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting

New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro...

AZN.LN : 10,680.000 (-1.11%)
AZN : 66.07 (-1.42%)
FGEN : 10.56 (-3.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 11,205.997
2nd Resistance Point 11,075.997
1st Resistance Point 10,937.999
Last Price 10,680.000
1st Support Level 10,670.001
2nd Support Level 10,540.001
3rd Support Level 10,402.003

See More

52-Week High 11,054.002
Last Price 10,680.000
Fibonacci 61.8% 9,898.451
Fibonacci 50% 9,541.501
Fibonacci 38.2% 9,184.551
52-Week Low 8,029.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar